Eprontia Oral Solution Approved for Partial-Onset, Primary Generalized Tonic-Clonic Seizures
Eprontia is approved for the treatment of partial-onset or primary generalized tonic-clonic seizures and migraine prevention.
Eprontia is approved for the treatment of partial-onset or primary generalized tonic-clonic seizures and migraine prevention.
To assess the benefits of topical capsaicin on SNC, the study authors performed a retrospective review that included 253 patients.
Study authors evaluated the impact on compliance and SNOT-20 scores in patients with allergic rhinitis using a novel sinus nasal rinse device.
Study authors analyzed the safety and efficacy of using MMA for patients undergoing head and neck surgery.
Study authors conducted a prospective randomized trial to determine if there is a role for oral steroids in patients who have CRSsNP.
Study authors conducted a retrospective cohort study of pediatric patients requiring operative control of PTH.
Study authors assessed whether the addition of a prednisone taper could decrease opioid use in patients undergoing tonsillectomy, tonsillectomy and adenoidectomy, or expansion sphincter pharyngoplasty.
Study authors conducted a retrospective analysis over a 5-year period to analyze health care resource utilization among CRSwNP patients and identify areas for quality improvement.
Researchers assessed whether patients with osteoarthritis and NSAID allergies have higher odds of developing opioid use disorder, and identified next steps to be considered for this patient population.
Investigators evaluated the relationship between atopic dermatitis and frequency of severity markers in patients hospitalized with COVID-19.